TRIPTODUR KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10166181 | AZURITY | Slow release pharmaceutical composition made of microgranules |
Jun, 2029
(5 years from now) | |
Triptodur Kit is owned by Azurity.
Triptodur Kit contains Triptorelin Pamoate.
Triptodur Kit has a total of 1 drug patent out of which 0 drug patents have expired.
Triptodur Kit was authorised for market use on 29 June, 2017.
Triptodur Kit is available in for suspension, extended release;intramuscular dosage forms.
The generics of Triptodur Kit are possible to be released after 30 June, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-149) | Jun 29, 2024 |
| Orphan Drug Exclusivity(ODE) | Jun 29, 2024 |
| New Product(NP) | Jun 29, 2020 |
Drugs and Companies using
TRIPTORELIN PAMOATE ingredient
Market Authorisation Date:
29 June, 2017Treatment:
NADosage:
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
More Information on Dosage
TRIPTODUR KIT family patents
